Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Serum expression of ESM-1 and Syndecan-1 and its relationship with disease severity in children with Mycoplasma pneumoniae pneumonia.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Source:
Publisher: BioMed Central Country of Publication: England NLM ID: 101510759 Publication Model: Electronic Cited Medium: Internet ISSN: 1824-7288 (Electronic) Linking ISSN: 17208424 NLM ISO Abbreviation: Ital J Pediatr Subsets: MEDLINE
- Publication Information:
Original Publication: London : BioMed Central
- Subject Terms:
- Abstract:
Competing Interests: Declarations. Ethics approval: The study was approved by the Ethics Committee of Children’s Hospital Affiliated to Zhengzhou University (Approval no. 2024-K-065). In addition, informed consent was obtained from the patients for the publication of all clinical data included in the main manuscript. Consent for publication: Written informed consent for publication was obtained from all participants. Conflict of interest: The authors have no conflicts of interest to disclose.
Background: This study aim to investigate the role of endothelial damage in the pathogenesis of Mycoplasma pneumoniae pneumonia (MPP) by comparing serum levels of endothelial cell-specific molecule 1 (ESM-1) and Syndecan-1 in patients with varying degrees of MPP severity. Additionally, we aim to explore the relationship between the production of ESM-1 and Syndecan-1 and the severity of MPP, inflammation, as well as hypercoagulative state in children.
Methods: A prospective, observational study that included clinical manifestations, laboratory tests, and serum ESM-1 and Syndecan-1 assays. The correlation between ESM-1 and Syndecan-1 levels with inflammatory markers and coagulation markers was analyzed. Multivariate logistic regression analysis was conducted to identify significant risk factors for Severe Mycoplasma pneumoniae pneumonia (SMPP).
Results: A total of 179 children with MPP and 40 healthy volunteers were enrolled. Serum ESM-1 and Syndecan-1 levels were significantly elevated in children with MPP compared to the healthy children (all P < 0.05). A multivariate analysis revealed that ESM-1, Syndecan-1, D-dimer and LDH were the significant predictors of SMPP, with odds ratios of 1.034, 1.002, 5.042 and 1.014, respectively. The optimal cutoff values of ESM-1, Syndecan-1, D-dimer and LDH for predicting SMPP were 79.67 ng/mL, 3219.35 pg/mL, 0.67 µg/mL and 365.00 U/L, respectively.
Conclusions: ESM-1, Syndecan-1, D-dimer, and LDH can serve as independent predictors for SMPP. The interaction between endothelial damage, excessive inflammatory response, and hypercoagulable state collectively contributes to the development and progression of SMPP.
(© 2025. The Author(s).)
- References:
Zhongguo Dang Dai Er Ke Za Zhi. 2013 Aug;15(8):619-22. (PMID: 23965872)
Pediatr Pulmonol. 2023 Oct;58(10):2815-2822. (PMID: 37431970)
Sci Rep. 2021 Apr 23;11(1):8864. (PMID: 33893369)
Eur Heart J. 2020 Sep 1;41(32):3038-3044. (PMID: 32882706)
Mol Med. 2021 Dec 3;27(1):151. (PMID: 34861818)
Eur Rev Med Pharmacol Sci. 2021 Jun;25(11):4091-4098. (PMID: 34156688)
Angiology. 2024 Feb;75(2):107-115. (PMID: 36680504)
Lancet Microbe. 2025 Apr;6(4):101019. (PMID: 40024259)
Front Cell Infect Microbiol. 2021 Jul 15;11:687391. (PMID: 34336714)
Adv Exp Med Biol. 2021;1321:33-43. (PMID: 33656711)
Am J Respir Crit Care Med. 2020 Aug 1;202(3):361-370. (PMID: 32101446)
Exp Ther Med. 2021 Mar;21(3):201. (PMID: 33574906)
Circ Res. 2021 Jun 11;128(12):2017-2036. (PMID: 34110909)
Pediatr Infect Dis J. 2024 Jun 1;43(6):505-510. (PMID: 38359345)
Hamostaseologie. 2024 Feb;44(1):21-30. (PMID: 38417802)
Nat Rev Cardiol. 2021 Sep;18(9):666-682. (PMID: 33958774)
Lancet Microbe. 2024 Jun;5(6):e515. (PMID: 38244553)
Exp Physiol. 2015 Feb 01;100(2):149-55. (PMID: 25523440)
Int Immunopharmacol. 2015 Sep;28(1):425-8. (PMID: 26184693)
Front Microbiol. 2021 Nov 19;12:766591. (PMID: 34867898)
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211010256. (PMID: 33942670)
Crit Care Explor. 2021 Mar 23;3(3):e0366. (PMID: 33786442)
Clin Microbiol Rev. 2017 Jul;30(3):747-809. (PMID: 28539503)
BMC Infect Dis. 2024 Apr 26;24(1):449. (PMID: 38671341)
Front Immunol. 2022 Dec 22;13:1088725. (PMID: 36618370)
BMC Infect Dis. 2022 Sep 6;22(1):724. (PMID: 36068499)
Am J Emerg Med. 2021 Apr;42:83-89. (PMID: 33493833)
BMC Infect Dis. 2020 Jan 16;20(1):51. (PMID: 31948402)
Acta Pharmacol Sin. 2023 Apr;44(4):695-709. (PMID: 36253560)
Pol Arch Med Wewn. 2012;122(11):557-66. (PMID: 23160102)
Indian J Pediatr. 2022 Oct;89(10):1003-1009. (PMID: 35665905)
Ital J Pediatr. 2023 Oct 20;49(1):143. (PMID: 37858230)
Ups J Med Sci. 2022 Jan 24;12:. (PMID: 35140869)
Ital J Pediatr. 2022 Aug 20;48(1):153. (PMID: 35987653)
J Thromb Haemost. 2023 Nov;21(11):3005-3015. (PMID: 37625698)
- Grant Information:
LHGJ 20210620 Henan Provincial Science and Technology Research Project; 2024YLZDJH358 Zhengzhou Science and Technology Innovation Guidance Project; NRMC0107 National Regional Medical Center Opening Project
- Contributed Indexing:
Keywords: ESM-1; Endothelial damage; Independent predictors; Severe Mycoplasma pneumoniae pneumonia; Syndecan-1
- Accession Number:
0 (Syndecan-1)
0 (ESM1 protein, human)
0 (Biomarkers)
0 (Proteoglycans)
0 (SDC1 protein, human)
0 (Neoplasm Proteins)
- Publication Date:
Date Created: 20250805 Date Completed: 20250806 Latest Revision: 20250808
- Publication Date:
20250808
- Accession Number:
PMC12326627
- Accession Number:
10.1186/s13052-025-02105-5
- Accession Number:
40764585
No Comments.